ETR:MDG1 - MediGene Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
€8.50 -0.05 (-0.58 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close€8.56
Today's Range€8.31 - €8.55
52-Week Range€8.53 - €19.27
Volume35,234 shs
Average Volume306,207 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 News and Ratings via Email

Sign-up to receive the latest news and ratings for MDG1 and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

MediGene (ETR:MDG1) Frequently Asked Questions

What is MediGene's stock symbol?

MediGene trades on the ETR under the ticker symbol "MDG1."

What price target have analysts set for MDG1?

3 Wall Street analysts have issued 12 month price targets for MediGene's shares. Their predictions range from €10.80 to €17.00. On average, they anticipate MediGene's share price to reach €13.93 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for MediGene.

What is the consensus analysts' recommendation for MediGene?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MediGene.

Has MediGene been receiving favorable news coverage?

News stories about MDG1 stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MediGene earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next few days.

Who are some of MediGene's key competitors?

Who are MediGene's key executives?

MediGene's management team includes the folowing people:
  • Prof. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 68)
  • Prof. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management Board
  • Dr. Thomas Taapken, CFO & Member of Exec. Management Board (Age 54)
  • Prof. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 78)
  • Dr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board

What is MediGene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €8.50.

What is MediGene's official website?

The official website for MediGene is

How can I contact MediGene?

MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.

MarketBeat Community Rating for MediGene (ETR MDG1)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote "Outperform" if you believe MDG1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDG1 will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel